Program
BREAK
FORUM
INVITED SYMPOSIUM
OTHER EVENT
PLENARY LECTURE
SPONSORED SYMPOSIUM
SYMPOSIUM
BREAK
FORUM
INVITED SYMPOSIUM
OTHER EVENT
PLENARY LECTURE
SPONSORED SYMPOSIUM
SYMPOSIUM
| Time | Hall A1 | Hall A2 | Auditorium 10+11 | Hall A3 | Auditorium 15 | Auditorium 12 | Exhibition |
|---|---|---|---|---|---|---|---|
| 08:30-10:30 |
SYMPOSIUM
|
BALANCING THE AD’S EQUATION: TAU, PROTEOSTASIS, AND VULNERABLE NETWORKS
|
GENETIC RISK AND MOLECULAR MECHANISMS IN AD
|
PROTEOMICS, LIPIDOMICS & RELATED MECHANISMS
|
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
|
INTEGRATING SLEEP, EEG, AND DIGITAL BIOMARKERS IN NEURODEGENERATION
|
|
| 10:30-11:00 |
COFFEE BREAK
|
||||||
| 11:00-13:00 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
PREVENTION AND RESILIENCE IN DEMENTIA AND AGING
|
α-SYNUCLEINOPATHIES MECHANISMS, PATHOPHYSIOLOGY: MODELING OF DISEASE PROGRESSION
|
FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD
|
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
|
SYMPOSIUM
|
|
| 13:00-14:00 |
LUNCH BREAK
|
||||||
| 14:00-15:30 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
BIOMARKERS AND NETWORKS OF RESILIENCE TO AD
|
IMMUNE–METABOLIC NETWORKS DRIVING TAU PATHOLOGY AND NEURODEGENERATION
|
THE APP PATHWAY: FROM HIDDEN FRAGMENTS TO THERAPEUTIC TARGETS IN AD
|
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
|
CHOLINERGIC MECHANISMS & TREATMENTS IN AD SPECTRUM
|
|
| 15:30-15:45 |
SHORT BREAK
|
||||||
| 15:45-16:45 |
PLENARY LECTURE 01, 02
|
||||||
| 16:45-17:00 |
SHORT BREAK
|
||||||
| 17:00-18:00 |
FIRESIDE DEBATE: INDUSTRY MEETS ACADEMIA: MOONSHOTS AND MILESTONES: IS THE FUTURE OF NEURODEGENERATION DRUG DISCOVERY IN STARTUPS, FOUNDATIONS, BIG PHARMA, OR ACADEMIA
|
||||||
| 18:05-19:10 |
ADPDTM CEREMONY AND AWARDS
|
||||||
| 19:20-21:00 |
WELCOME RECEPTION IN EXHIBITION
|
| Time | Hall A1 | Hall A2 | Auditorium 10+11 | Hall A3 | Auditorium 15 | Auditorium 12 | Exhibition |
|---|---|---|---|---|---|---|---|
| 08:00-08:30 |
PLENARY LECTURE 03: DON PRICE MEMORIAL LECTURE
|
||||||
| 08:30-08:40 |
BREAK
|
||||||
| 08:40-10:40 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
MICROGLIA/ASTROGLIA FROM MECHANISMS TO POTENTIAL TREATMENTS
|
ALPHA-SYNUCLEIN, AGGREGATION, MISFOLDING, PATHOGENESIS AND TRANSLATIONAL ASPECTS
DECODING APOE: GENETICS, LIPIDS, AND DISEASE
|
TRANSLATIONAL DRUG DISCOVERY AND MODELS
|
WHITE MATTER SIGNATURES IN NEURODEGENERATION AND PROGNOSIS
|
||
| 10:40-11:10 |
EXHIBITION, POSTERS AND COFFEE BREAK
|
||||||
| 11:10-12:50 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
||||||
| 12:50-14:30 |
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
|
||||||
| 14:30-15:30 |
FORUM 01: BIOMARKERS TO BENEFIT: ACCELERATING TRANSLATION OF MULTI-MODAL BIOMARKERS INTO DISEASE-MODIFYING THERAPIES
|
||||||
| 14:30-16:30 |
DECODING THE AMYLOID–TAU AXIS IN AD
|
MITOCHONDRIAL PATHWAYS IN NEURODEGENERATION AND THERAPY
|
PREDICTING PD & LBD: BIOMARKERS AND BEYOND
|
REWIRING NEUROINFLAMMATION: MICROGLIA AND IMMUNE THERAPEUTICS
|
GENOMIC LANDSCAPES IN AD, PD, AND DEMENTIA
|
||
| 15:35-16:35 |
FORUM 02: BEYOND ONE SIZE FITS ALL: PRECISION DRUG DEVELOPMENT, AI METHODS, AND TRIAL DESIGN IN AD/PD
|
||||||
| 16:30-17:00 |
EXHIBITION, POSTERS AND COFFEE BREAK
|
||||||
| 17:00-19:00 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
FLUID BIOMARKERS AND MULTIMODAL IMAGING: DIAGNOSIS, PROGNOSIS AND DISEASE PROGRESSION
|
GENETIC LANDSCAPES OF ALZHEIMER’S AND PARKINSON’S
FROM RISK TO RESILIENCE IN COGNITIVE DECLINE
|
FUNCTIONAL AND STRUCTURAL IMAGING IN NEURODEGENERATION
|
CAA AND BBB DYSFUNCTION: DIAGNOSIS, RISK FACTORS AND CELLULAR CHANGES
|
| Time | Hall A1 | Hall A2 | Auditorium 10+11 | Hall A3 | Auditorium 15 | Auditorium 12 | Exhibition |
|---|---|---|---|---|---|---|---|
| 08:00-08:30 |
PLENARY LECTURE 04
|
||||||
| 08:30-08:40 |
BREAK
|
||||||
| 08:40-10:40 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
MECHANISMS AND THERAPEUTICS IN THE ALS–FTD SPECTRUM (SOD-1, TDP-43, C9ORF72 AND TMEM106B)
|
MECHANISTIC INSIGHTS INTO PD AND LBD PATHOLOGY
|
MECHANISTIC INSIGHTS INTO SEX DIFFERENCES IN NEURODEGENERATION
|
PERIPHERAL AND CENTRAL IMMUNITY ACROSS AD/PD
|
LIPIDS, APOE IN AD, PD & MS
|
|
| 10:40-11:10 |
EXHIBITION, POSTERS AND COFFEE BREAK
|
||||||
| 11:10-12:50 |
SYMPOSIUM
|
||||||
| 12:50-13:50 |
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
|
||||||
| 13:50-15:50 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
INFLAMMATION, LIPIDS, AND GLIAL PATHWAYS IN DEMENTIA
|
GENETIC AND CELLULAR PATHWAYS - FROM LRRK2 TO LBD AND PD
|
AI AND DIGITAL TOOLS FOR AD/PD CARE
|
DECODING TAU AND ITS CELLULAR PARTNERS IN DISEASE
|
SYMPOSIUM
|
|
| 15:50-16:20 |
EXHIBITION, POSTERS AND COFFEE BREAK
|
||||||
| 16:20-17:20 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
||||||
| 16:20-18:20 |
ARIA AND CAA: MECHANISMS
|
LINKING PATHOLOGY AND BIOMARKERS ACROSS NEURODEGENERATIVE DISORDERS
|
PET AND MULTIMODAL IMAGING IN AD, PD, AND LBD
|
GUT–BRAIN AXIS IN AD AND PD
|
FLUID BIOMARKERS AND MULTIMODAL IMAGING
|
||
| 17:30-18:30 |
FORUM 03: REWIRING COGNITION: TARGETING CHOLINERGIC, SYNAPTIC, AND NETWORK-BASED MECHANISMS IN AD, PD, AND LBD
|
| Time | Hall A1 | Hall A2 | Auditorium 10+11 | Hall A3 | Auditorium 15 | Auditorium 12 | Exhibition |
|---|---|---|---|---|---|---|---|
| 08:00-08:30 |
PLENARY LECTURE 05
|
||||||
| 08:30-08:40 |
BREAK
|
||||||
| 08:40-10:40 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
CHOLINERGIC PATHWAYS: FROM MECHANISMS TO TREATMENTS
|
SYNAPTIC DYSFUNCTION AND BIOMARKERS IN AD/PD
|
APOE 4 DISTICT SIGNATURE IN AD AND PD
|
PROTEIN AGGREGATES, NEUROGENESIS, AND TRANSLATIONAL OPPORTUNITIES
|
GENETICS, APOE AND LIPID PATHWAYS IN AD
|
|
| 10:40-11:10 |
EXHIBITION, POSTERS AND COFFEE BREAK
|
||||||
| 11:10-12:50 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
||||||
| 12:50-13:50 |
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
|
||||||
| 13:50-15:50 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
ABETA TARGETING THERAPIES IN AD: PROGRESS AND PERSPECTIVES
|
GENETIC INSIGHTS IN AD, PD AND PSYCHIATRIC DISORDERS
|
CEREBROVASCULAR CHANGES, CAA, BBB
|
FLUID BIOMARKERS AND IMAGING - LINKING MECHANISMS TO CARE
|
SYMPOSIUM: LATE BREAKING ABSTRACTS
|
|
| 15:50-16:20 |
EXHIBITION, POSTERS AND COFFEE BREAK
|
||||||
| 16:20-17:20 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
||||||
| 16:20-18:20 |
TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS
|
PET, MULTIMODAL IMAGING AND BIOMARKERS IN CLINICAL USE ACROSS DEMENTIAS
|
ARIA AND CAA: BIOMARKERS
|
LYSOSOMAL STORAGE DISEASES AND ENDOLYSOSOMAL PROTEOSTASIS MECHANISMS
|
MECHANISMS AND PATHWAYS TO THERAPY IN AD, FTD, AND ALS
|
||
| 17:30-18:30 |
FORUM 04: TARGETS TO THERAPIES: TRANSLATIONAL R&D FOR Α-SYNUCLEIN, LRRK2, AND GBA PATHOLOGIES IN PD, LBD, AND MSA
|
||||||
| 18:30-18:40 |
SHORT BREAK
|
||||||
| 18:40-19:40 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
COGNITIVELY HEALTHY CENTENARIANS: HOW DO THEY DO IT?
|
AD: GENETIC RISK AND BEYOND
|
AI, GENOTYPING, AND DIGITAL TOOLS IN NEURODEGENERATION
|
MODELING NEURODEGENERATIVE DISEASE IN PRIMATES
|
PSP IN FOCUS: MECHANISMS, MEASURES, AND MEDICINES
|
| Time | Hall A1 | Hall A2 | Auditorium 10+11 | Hall A3 | Auditorium 15 | Auditorium 12 | Exhibition |
|---|---|---|---|---|---|---|---|
| 08:00-08:30 |
PLENARY LECTURE 06
|
||||||
| 08:30-08:40 |
BREAK
|
||||||
| 08:40-10:40 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
ANTI-AMYLOID IMMUNOTHERAPY: MECHANISMS AND PRACTICE
|
TAU BIOLOGY AND THERAPEUTIC STRATEGIES
|
GLP-1 MECHANISMS AND THERAPEUTICS IN NEURODEGENERATION
|
RESTORING NEURAL RESILIENCE IN ALS AND ALZHEIMER’S DISEASE
|
NEXT-GENERATION BIOMARKERS ACROSS AD, PD, AND LBD
|
|
| 10:40-11:10 |
EXHIBITION, POSTERS AND COFFEE BREAK
|
||||||
| 11:10-13:10 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
ANTIBODIES & SHUTTLES FOR TARGETED BRAIN DELIVERY
|
PD AND LEWY BODY DISORDERS: FROM PREVENTION TO NOVEL THERAPIES
|
MICROGLIA AND NEUROIMMUNE TARGETS IN AD, FTD AND PD
|
BIOMARKER SIGNATURES IN PRECLINICAL AD AND NEURODEGENERATIVE DISEASES
|
TARGETING TAU: MECHANISMS AND THERAPIES
|
|
| 13:10-14:10 |
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
|
||||||
| 14:10-16:10 |
ADVANCES IN AD TREATMENT
|
EMERGING THERAPIES ACROSS AD, PD, LBD
|
TRANSLATIONAL TREATMENT STRATEGIES IN AD & FTD; NEW TARGETS
|
FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD, HD
|
MOLECULAR SIGNATURES AND CONFORMATIONAL STATES IN AD AND LBD
|
||
| 14:10-15:10 |
INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)
|
||||||
| 15:30-16:30 |
FORUM 05: IMMUNOTHERAPY 2.0: REDEFINING MICROGLIAL, TREM2, AND ADAPTIVE IMMUNE ENGAGEMENT IN AD AND PD
|
||||||
| 16:30-17:00 |
EXHIBITION, POSTERS AND COFFEE BREAK
|
||||||
| 17:00-19:05 |
TAU, AMYLOID, AND SYNUCLEIN: MECHANISMS AND TREATMENTS
|
INTEGRATING IMAGING AND BIOMARKERS IN AD, PD, AND LBD
|
PROTECTIVE AND PATHOLOGICAL PATHWAYS IN COGNITIVE DECLINE
|
MOLECULAR MECHANISMS AND EMERGING THERAPIES IN PD, MSA AND LBD
|
TRACKING PD, GBA-PD AND MSA BIOMARKERS, MECHANISMS, AND PROGRESSION
|
||
| 18:05-19:05 |
FORUM 06: BEYOND AMYLOID AND TAU: EMERGING TARGETS AND MULTI-PATHWAY APPROACHES IN NEURODEGENERATION AND NEUROINFLAMMATION – PROMISE AND PITFALLS
|
||||||
| 19:05-19:15 |
CLOSING SESSION
|